Wayshine (Hangzhou) Biopharm Co., Ltd. (hereinafter “Wayshine Biopharm”) was established in 2016 as a Biopharm enterprise that proactively and strategically advances the R&D of innovative oncology drugs with a global vision. The group’s parent company is registered in Delaware, USA, with overseas entities in California, USA, and Hong Kong. As the group’s domestic headquarters, Wayshine Biopharm is based in Xujiahui, Shanghai, and operates subsidiaries including Shanghai Weidao and Hangzhou Weiruibo, thereby forming a global R&D and operational footprint spanning China and the United States.
Positioned at the forefront of Biopharms, the company focuses on brain tumors and solid tumors, having established a core technology platform for efficient blood-brain barrier (BBB) penetration with a comprehensive R&D system spanning “target discovery — target validation — compound design — preclinical development.” The core product, WSD0922, is an EGFR/EGFRvIII targeted inhibitor with BBB-penetrating capability for indications including non-small cell lung cancer (NSCLC) and glioma. It has obtained FDA clinical trial clearance and is conducting Phase I/II clinical trials in the United States in collaboration with the internationally renowned Mayo Clinic. The domestic clinical program has advanced to Phase III and has been granted NMPA Breakthrough Therapy Designation (BTD). The company has completed multiple rounds of financing from prominent USD-denominated funds, continuously accelerating the advancement and internationalization of its forward-looking R&D pipeline.
